Innate Pharma - ADR
IPHA
Get informed when a big investor buys or sells
+ FollowMarket Cap$152.12M
Close$
$-0.15
110% downside
Current Fair Value
110% downsideOvervalued by 110% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $152.12 Million |
|---|---|
| Enterprise Value | $156.49 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.53 |
| Beta | 0.88 |
| Outstanding Shares | 93,826,793 |
Return
| Return on Equity | 231.07% |
|---|---|
| Return on Assets | -269.55% |
| Return on Invested Capital | -5416.42% |
Valuation & Multiples
| P/E Ratio | -2.55 |
|---|---|
| PEG | 37.4 |
| Price to Sales | - |
| Price to Book Ratio | -1.48 |
| Enterprise Value to Revenue | 16.65 |
| Enterprise Value to EBIT | -1.55 |
| Enterprise Value to Net Income | -2 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | -0.27 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
September 17, 2026
EPS Estimate
$-0.29
Average shareholder expectationRevenue Estimate
$6.35 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.22%▲ 0.01% |
|---|---|
| Total Invested | $354,047▲ 50.37% |
| Investors Holding | 10▲ 1.00% |
ESG Score
No data
About Innate Pharma
244 employees
CEO: Mondher Mahjoubi Innate Pharma S.A. is a biotechnology firm dedicated to the discovery, development, and commercialization of innovative antibody-based therapies, primarily for cancer indications, operating both in France and internationally. The company...